Identification and biological applications of rhegnylogically-organized cell penetrating peptides. by Howl, John D. & Jones, Sarah
Proceedings of the 4th International Peptide Symposium 
in conjunction with the 7th Australian Peptide Conference 
and the 2nd Asia-Pacific International Peptide Symposium, 2007 
1 
Jackie Wilce (Editor) on behalf of the 
Australian Peptide Association 
Identification and biological applications of 
rhegnylogically-organized cell penetrating peptides 
 
John Howl and Sarah Jones 
Research Institute in Healthcare Science, University of Wolverhampton, Wolverhampton, WV1 2SB, U.K. 
E-mail: J.Howl@wlv.ac.uk 
 
Introduction 
  Many different cell penetrating peptides (CPPs) have 
been utilized as vectors to affect the highly efficient 
intracellular delivery of bioactive moieties. A majority of 
such studies employ sychnologically-organized tandem 
combinations of a cargo (message) and a CPP 
(address).  To date, bioactive cargoes have included 
peptides (Fig. 1), proteins and a range of oligonucleotides 
attached either by direct chemical conjugation or as a 
component of a larger macromolecular complex. 
Moreover, a majority of CPPs, including the commonly 
used sequences Tat and penetratin, are designed to be both 
biologically and toxicologically inert. 
  More recently, a QSAR-based algorithm has been 
developed to predict cryptic polycationic CPP motifs 
within the primary sequences of proteins [1]. As described 
here, this novel technology has enabled the study of 
rhegnylogic CPPs in which multiple pharmacophores for 
cellular penetration and desirable biological activities are 
discontinuously organized within the primary sequence of 
single peptide. This organization differs from the more 
commonly utilized sychnologic strategy which joins 
functionally discrete and continous address and messages 
together in a tandem construct. 
  
         Address          Message 
    
 
    
 
Fig. 1. Comparative organization of sychnologic (Top) and 
rhegnylogic (Bottom) CPP constructs 
Results and Discussion  
A cell penetrant modulator of heterotrimeric    
G proteins 
  Type 2 G protein-coupled receptors include a family of 
proteins that bind peptide ligands which are structurally 
related to calcitonin. The 20 amino acid sequence, 
H-RKLTTIFPLNWKYRKALSLG-NH2, predicted as a 
highly probable CPP, is located within the first 
intracellular loop of the human type a calcitonin receptor 
hCTRa. This sequence, hCTRa174-193, includes a splice 
variant 16 amino acid insert that modulates the 
pharmacology of hCTRs [2].When added exogenously to 
cells expressing hCTRa, the peptide hCTRa174-193 (1 mM) 
independently stimulated cAMP formation and also 
augmented calcitonin-induced cAMP synthesis. This 
mechanism involves the direct activation of heterotrimeric 
G proteins by hCTRa174-193. Confocal microscopy, 
employing hCTRa174-193 labeled with fluorescein at the 
amino terminal, confirmed that hCTRa174-193 efficiently 
translocated the plasma membrane of EVC304 human 
bladder cancer cells (Fig. 2). Additional investigations to 
determine the G protein selectivity of hCTRa174-193 are 
currently in progress.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Intracellular distribution of flouresceinyl-hCTRa174-193 
Human Cytochrome c as a CPP prediction 
template 
  The rhegnylogic strategy was also applied to 
cytochrome c (Cyt c), a signaling protein that is integral to 
intrinsic apoptotic events. As illustrated by the examples 
below, highly probable CPPs predicted within the primary 
sequence of Cyt c were restricted in distribution to major 
helical domains at the amino- and carboxyl- termini of the 
protein (Fig. 3). 
 
      Sequence               Position 
  EKGKKIFIMK        Cyt c4-13 
  KKKEERADLIAYLKKA       Cyt c86-101 
  GTKMIFVGIKKKEERADLIAYLKKA    Cyt c77-101 
  KMIFVGIKKKEERA             Cyt c79-92 
 
Fig. 3. Predicted CPPs within human cytochrome c 
 
The properties of two CPPs from the C-terminal helix of 
human Cyt c, Cyt c77-101 and the shorter homologue Cyt 
c86-101, indicate that these CPPs can effectively target 
different intracellular domains. Thus, confocal imaging 
revealed that rhodamine-conjugated Cyt c77-101 assumed a 
cytoplasmic distribution and was co-localized with both 
endoplasmic reticulum and mitochondria. Moreover,   
Cyt c77-101 did not co-localize with the intracellular 
Proceedings of the 4th International Peptide Symposium 
in conjunction with the 7th Australian Peptide Conference 
and the 2nd Asia-Pacific International Peptide Symposium, 2007 
2 
Jackie Wilce (Editor) on behalf of the 
Australian Peptide Association 
endosomal compartment, a feature that may restrict the 
utility of other CPPs including Tat. Cyt c77-101 was also 
excluded from the nucleus of living cells (Fig. 4). In 
contrast, rhodamine-conjugated Cyt c86-101 specifically 
located within the nucleus of U373MG astrocytoma cells 
and comparative little fluorescent peptide was observed in 
other cellular compartments (Fig. 4). 
      
          A                        B 
 
 
 
 
 
 
 
 
 
Fig. 4. Intracellular distribution of Cyt c77-101(A) and      
Cyt c86-101(B) in living U373MG cells 
 
Additional studies indicated that both Cyt c77-101 and    
Cyt c86-101 reduced the viability of U373MG astrocytoma 
by the specific induction of apoptosis. These findings 
indicate that these peptides can mimic the apoptogenic 
activity of the native protein 
  As human Cyt c contains at least two domains that 
harbor cryptomic cell penetrant motifs, we also 
investigated whether exogenously applied Cyt c could 
penetrate cells. Horse spleen Cyt c was labeled with FITC 
[3] and purified by dialysis. As shown below (Fig. 5), 
mono-labeled Cyt c protein readily translocated the plasma 
membrane of U373 MG cells to assume both a cytoplasmic 
and nuclear distribution. In contrast to the observed 
distribution of Cyt c-derived peptides (see above), a major 
component of translocated Cyt c was distributed within the 
endosomal compartment of living cells. 
 
 
 
 
 
 
                    
 
 
 
 
 
 
 
 
 
 
Fig. 5. Intracellular distribution of Cyt c protein in living   
U373 MG cells 
  These observations indicate that the native Cyt c protein 
enters cells by a predominantly endosomal route of import, 
whilst the cell penetrant fragments Cyt c77-101 and      
Cyt c86-101 utilize an alternative route. However, it is 
obvious that a significant fraction of translocated Cyt c 
protein is able to escape the endosomal compartment to 
re-locate within the nucleus. This intracellular trafficking 
reflects the known movement of Cyt c when it is released 
from mitochondria during apotosis [4]. 
 
Endothelial cell modulation by eNOS492-507 
  The calcium-calmodulin (CaM) complex modulates the 
activity of a variety of protein targets including the 
endothelial isozyme of nitric oxide synthase (eNOS). More 
recently, x-ray crystallographic structures have indicated 
that a 20 amino acid peptide from eNOS forms a stable 
complex with CaM [5]. Using the QSAR-based prediction 
algorithm [1], we determined that a 4 amino acid-deleted 
homologue of this peptide, eNOS492-507, would have 
efficient cell penetrating properties. Moreover, this peptide 
(H-RKKTFKEVANAVKISA-NH2) has unique properties 
as a novel modulator of endothelial cell function. Thus, 
eNOS492-507 potently (10-100 nM) inhibits the proliferation, 
migration and tube forming capacity of bovine aortic 
endothelial cells stimulated with fibroblast growth factor-2 
(FGF-2). Furthermore, the same peptide inhibits FGF-2 
stimulated angiogenesis in vivo and could, therefore, have 
therapeutic potential. 
We conclude that the rhegnylogically-organized CPPs 
are valuable probes of biological phenomena. 
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